Literature DB >> 11774263

Altered adhesion properties and alphav integrin expression in a cisplatin-resistant human ovarian carcinoma cell line.

Sylvie Maubant1, Séverine Cruet-Hennequart, Laurent Poulain, Franck Carreiras, François Sichel, José Luis, Cathy Staedel, Pascal Gauduchon.   

Abstract

In order to elucidate the mechanisms underlying the development of chemoresistance in ovarian cancer, we have previously established the IGROV1-R10 cisplatin-resistant cell line by mimicking a clinical protocol of drug administration on IGROV1 human ovarian carcinoma cells. Both IGROV1 and IGROV1-R10 cells were able to grow as a monolayer and to release cell clusters into the medium. However, IGROV1-R10 cells exhibited an enhanced capacity to detach from the monolayer as compared to the parental cells. When substrate adhesion was prevented, IGROV1-R10 cells were able to survive and to proliferate as cell clusters, even at a low cell density, whereas IGROV1 cells massively died. To explore the underlying mechanisms, we have been interested in alphav integrins, which have been implicated in some aspects of ovarian cancer biology. Both IGROV1 and IGROV1-R10 adherent cells expressed alphavbeta3 integrin. During cell growth, alphavbeta5 integrin accumulated at the surface of a majority of IGROV1-R10 cells from the monolayer, whereas only a faint expression of this integrin was observed in a minority of IGROV1 cells. The growth of IGROV1-R10 cells, but not of IGROV1 cells, was partly inhibited by a specific alphavbeta5-blocking antibody suggesting that alphavbeta5 integrin contributed to IGROV1-R10 cell proliferation. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11774263     DOI: 10.1002/ijc.1600

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  17 in total

1.  Role of RGD-containing ligands in targeting cellular integrins: Applications for ovarian cancer virotherapy (Review).

Authors:  Lena J Gamble; Anton V Borovjagin; Qiana L Matthews
Journal:  Exp Ther Med       Date:  2010-03       Impact factor: 2.447

2.  A prognostic gene signature in advanced ovarian cancer reveals a microfibril-associated protein (MAGP2) as a promoter of tumor cell survival and angiogenesis.

Authors:  Kristin A Spivey; Jacqueline Banyard
Journal:  Cell Adh Migr       Date:  2010-04-05       Impact factor: 3.405

3.  Expression of alpha V-associated integrin beta subunits in epithelial ovarian cancer and its relation to prognosis in patients treated with platinum-based regimens.

Authors:  Sylvie Maubant; Séverine Cruet-Hennequart; Soizic Dutoit; Yves Denoux; Hubert Crouet; Michel Henry-Amar; Pascal Gauduchon
Journal:  J Mol Histol       Date:  2005-02       Impact factor: 2.611

4.  High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer.

Authors:  Marcus Bernardini; Chung-Hae Lee; Ben Beheshti; Mona Prasad; Monique Albert; Paula Marrano; Heather Begley; Patricia Shaw; Al Covens; Joan Murphy; Barry Rosen; Salomon Minkin; Jeremy A Squire; Pascale F Macgregor
Journal:  Neoplasia       Date:  2005-06       Impact factor: 5.715

5.  Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer.

Authors:  Charles N Landen; Tae-Jin Kim; Yvonne G Lin; William M Merritt; Aparna A Kamat; Liz Y Han; Whitney A Spannuth; Alpa M Nick; Nicholas B Jennnings; Michael S Kinch; David Tice; Anil K Sood
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

6.  A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2.

Authors:  Samuel C Mok; Tomas Bonome; Vinod Vathipadiekal; Aaron Bell; Michael E Johnson; Kwong-kwok Wong; Dong-Choon Park; Ke Hao; Daniel K P Yip; Howard Donninger; Laurent Ozbun; Goli Samimi; John Brady; Mike Randonovich; Cindy A Pise-Masison; J Carl Barrett; Wing H Wong; William R Welch; Ross S Berkowitz; Michael J Birrer
Journal:  Cancer Cell       Date:  2009-12-08       Impact factor: 31.743

Review 7.  The tumor microenvironment is a dominant force in multidrug resistance.

Authors:  Ana Luísa Correia; Mina J Bissell
Journal:  Drug Resist Updat       Date:  2012-02-13       Impact factor: 18.500

8.  External validation suggests Integrin beta 3 as prognostic biomarker in serous ovarian adenocarcinomas.

Authors:  Karolina Partheen; Kristina Levan; Lovisa Osterberg; Ingela Claesson; Karin Sundfeldt; György Horvath
Journal:  BMC Cancer       Date:  2009-09-23       Impact factor: 4.430

9.  Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer.

Authors:  Meng Li; Curt Balch; John S Montgomery; Mikyoung Jeong; Jae Hoon Chung; Pearlly Yan; Tim H M Huang; Sun Kim; Kenneth P Nephew
Journal:  BMC Med Genomics       Date:  2009-06-08       Impact factor: 3.063

10.  Matched rabbit monoclonal antibodies against αv-series integrins reveal a novel αvβ3-LIBS epitope, and permit routine staining of archival paraffin samples of human tumors.

Authors:  Simon L Goodman; Hans Juergen Grote; Claudia Wilm
Journal:  Biol Open       Date:  2012-02-06       Impact factor: 2.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.